Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ezetimibe in human plasma and pharmaceutical formulations

被引:35
作者
Oliveira, PR
Brum, L
Fronza, M
Bernardi, LS
Masiero, SMK
Dalmora, SL [1 ]
机构
[1] Univ Fed Santa Maria, Dept Ind Pharm, BR-97105900 Santa Maria, RS, Brazil
[2] Univ Fed Santa Maria, Hlth Sci Ctr, Postgrad Program Pharmaceut Sci, BR-97105900 Santa Maria, RS, Brazil
关键词
column liquid chromatography-mass spectrometry-MS; liquid-liquid extraction; ezetimibe in human plasma; method validation;
D O I
10.1365/s10337-006-0749-2
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An analytical method based on liquid chromatography-tandem mass spectrometry (LC-MS-MS) was developed and validated for the determination of ezetimibe in human plasma. Ezetimibe and etoricoxib (internal standard) were extracted from the plasma by liquid-liquid extraction and separated on a C-18 analytical column (50 x 3.0 mm I.D.) with acetonitrile:water (85:15, v/v) as mobile phase. Detection was carried out by positive electrospray ionization (ESI+) in multiple reaction monitoring (MRM) mode. The chromatographic separation was obtained within 2.0 min and was linear in the concentration range of 0.25-20ng mL(-1) for free ezetimibe and of 1-300ng mL(-1) for total ezetimibe. The mean extraction recoveries for free and total ezetimibe from plasma were 96.14 and 64.11%, respectively. Method validation investigated parameters such as linearity, precision, accuracy, specificity and stability, giving results within the acceptable range. The proposed method was successfully applied to the quantitation of ezetimibe and its glucuronide in human plasma to support clinical and pharmacokinetic studies. Moreover, the method was used for the quality control analysis of pharmaceutical dosage forms.
引用
收藏
页码:315 / 320
页数:6
相关论文
共 8 条
[1]   Ezetimibe: a selective inhibitor of cholesterol absorption [J].
Catapano, AL .
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2001, 3 (0E) :E6-E10
[2]   The discovery of ezetimibe: A view from outside the receptor [J].
Clader, JW .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (01) :1-9
[3]  
Davis H.R., 2004, International Congress, V1262, P243
[4]   A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe [J].
Ezzet, F ;
Krishna, G ;
Wexler, DB ;
Statkevich, P ;
Kosoglou, T ;
Batra, VK .
CLINICAL THERAPEUTICS, 2001, 23 (06) :871-885
[5]  
*GUID IND, 2001, BIOAN METH VAL US DE
[6]   Pharmaceutical applications of liquid chromatography coupled with mass spectrometry (LC/MS) [J].
Lee, H .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2005, 28 (7-8) :1161-1202
[7]   Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms [J].
Sistla, R ;
Tata, VSSK ;
Kashyap, YV ;
Chandrasekar, D ;
Diwan, PV .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (3-4) :517-522
[8]   Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: Assay development, validation and application to a clinical study [J].
Trivedi, RK ;
Kallem, RR ;
Mullangi, R ;
Srinivas, NR .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 39 (3-4) :661-669